305 results
Search Results
2. Nanomedicine and nanobiotechnology in India.
- Author
-
Pan D
- Subjects
- Nanotechnology, Drug Delivery Systems, India, Nanomedicine, Nanostructures
- Abstract
Nanomedicine, an interdisciplinary field combining nanotechnology and medicine, has gained immense attention in recent years due to its potential in revolutionizing healthcare. India, being an emerging hub for scientific research and development, has made significant strides in nanomedicine research. This special issue is dedicated to the exciting research that are being conducted by the leading Indian scientists in various Indian institutions. This article is categorized under: Biology-Inspired Nanomaterials > Lipid-Based Structures Therapeutic Approaches and Drug Discovery > Emerging Technologies., (© 2024 Wiley Periodicals LLC.)
- Published
- 2024
- Full Text
- View/download PDF
3. Investigating the potential application of organic and non-organic nanoparticles for gastric cancer treatment: An evidence-based review.
- Author
-
Moradifar, N., Moayyedkazemi, A., Mohammadi, H. R., Ahmadi, S., and Raziani, Y.
- Subjects
STOMACH cancer ,NANOPARTICLES ,METAL nanoparticles ,CANCER treatment ,CANCER-related mortality - Abstract
Gastric cancer, which is considered a major health concern, is the sixth most frequent cancer and the second leading cause of cancer-related mortality across the globe. The present survey aimed to systematically review the anti-gastric cancer effect of all organic and inorganic nanoparticles (NPs) in in vitro, in vivo, and clinical trials. The investigation followed the PRISMA guidelines, and the findings were recorded in the CAMARADES-NC3Rs Preclinical Systematic Review and Meta-Analysis Facility database. A detailed search was conducted on various English databases, such as Scopus, Web of Science, EMBASE, PubMed, and Google Scholar, with no specified publication time frame to obtain papers regarding the anti-gastric cancer properties of nanoparticles. The search process was performed using the following terms: "Nanoparticles," "Gastric cancer," "Antigastric cancer," "Metal nanoparticles," "Organic nanoparticles," "Inorganic nanoparticles, "in vitro," "Clinical," and "in vivo,". Out of 11,189 papers, 31 articles, including 19 (45.5%) in vitro, 3 (13.6%) in vivo, 3 (13.6%) clinical trials, and 6 (27.3%) in vitro/in vivo, up to 2023, met the inclusion criteria for discussion in this systematic review. The most widely used NPs were found to be organic nanoparticles, such as polylactic acid and poly lactic-co-glycolic acid (16, 80.0%), followed by inorganic nanoparticles, such as silver NPs (13, 41.9.0%). This review study highlighted the high anti-gastric cancer potential of a wide range of organic and non-organic NPs through their activity via some mechanisms, such as the induction of apoptosis, gene therapy, and drug delivery. Nonetheless, further studies, especially in clinical settings, are needed to confirm their anti-gastric effects and accurate mechanisms. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. Radiolabeled Tracing Techniques Illuminating Blood Pharmacokinetics in Nanomedicine.
- Author
-
Wenyao Zhou, Jun Zhang, Xinyu Wang, and Min Yang
- Subjects
NANOMEDICINE ,PHARMACOKINETICS ,RADIOLABELING ,NANOTECHNOLOGY ,FETAL monitoring - Abstract
In the realm of pharmaceutical advancement, the transformative prowess of nanotechnology shines through its precision-targeted drug delivery and amplified therapeutic effects. This paper ventures into the realm of radiolabeling techniques for unraveling the intricate choreography of drug kinetics within the bloodstream which encompass the delicate stages of absorption, distribution, metabolism, and excretion. Through the magical lens of the radiolabel, a real-time spectacle unfolds, providing invaluable insights into the safety and efficacy of nanomedicine interventions. Amid the labyrinthine complexities of drug-organism interactions and the lack of universal protocols for nanomedicine preparation, radiolabeling technology has emerged as a guiding constellation. The paper systematically assesses the methods commonly employed for pharmacokinetic studies, delves into the manifold advantages and techniques of radiolabel methods within the nanomedicine landscape, closely examines their application across a spectrum of pharmacokinetic studies and thoughtfully addresses the challenges they may pose. Embark on this illuminating odyssey--a journey that peers into the microcosm of nanomedicine, deciphering its dynamic interplay within the bloodstream through the luminary insights of radiolabeled tracing techniques. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
5. Nanotechnology in medicine revolutionizing drug delivery for cancer and viral infection treatments.
- Author
-
Karahmet Sher E, Alebić M, Marković Boras M, Boškailo E, Karahmet Farhat E, Karahmet A, Pavlović B, Sher F, and Lekić L
- Subjects
- Humans, Animals, Nanoparticles, Antineoplastic Agents administration & dosage, Antineoplastic Agents chemistry, Antiviral Agents administration & dosage, Antiviral Agents chemistry, Neoplasms drug therapy, Virus Diseases drug therapy, Nanotechnology methods, Drug Delivery Systems methods, Nanomedicine methods
- Abstract
Advancements in nanotechnology were vastly applied in medicine and pharmacy, especially in the field of nano-delivery systems. It took a long time for these systems to ensure precise delivery of very delicate molecules, such as RNA, to cells at concentrations that yield remarkable efficiency, with success rates reaching 95.0% and 94.5%. These days, there are several advantages of using nanotechnological solutions in the prevention and treatment of cancer and viral infections. Its interventions improve treatment outcomes both due to increased effectiveness of the drug at target location and by reducing adverse reactions, thereby increasing patient adherence to the therapy. Based on the current knowledge an updated review was made, and perspective, opportunities and challenges in nanomedicine were discussed. The methods employed include comprehensive examination of existing literature and studies on nanoparticles and nano-delivery systems including both in vitro tests performed on cell cultures and in vivo assessments carried out on appropriate animal models, with a specific emphasis on their applications in oncology and virology. This brings together various aspects including both structure and formation as well as its association with characteristic behaviour in organisms, providing a novel perspective. Furthermore, the practical application of these systems in medicine and pharmacy with a focus on viral diseases and malignancies was explored. This review can serve as a valuable guide for fellow researchers, helping them navigate the abundance of findings in this field. The results indicate that applications of nanotechnological solutions for the delivery of medicinal products improving therapeutic outcomes will continue to expand., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
6. Dual-molecular targeting nanomedicine upregulates synergistic therapeutic efficacy in preclinical hepatoma models.
- Author
-
Wang Q, Sun X, Fang X, Wang Z, Wang H, Sun S, Wang S, Li T, Zhang P, and Cheng Z
- Subjects
- Animals, Humans, Metformin pharmacology, Molecular Targeted Therapy, Mice, Nude, Mice, Drug Synergism, Cell Line, Tumor, Polyethylene Glycols chemistry, Xenograft Model Antitumor Assays, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Mice, Inbred BALB C, Carcinoma, Hepatocellular drug therapy, Carcinoma, Hepatocellular pathology, Sorafenib pharmacology, Liver Neoplasms drug therapy, Liver Neoplasms pathology, Nanomedicine, Micelles
- Abstract
Advanced hepatocellular carcinoma (HCC) is one of the most challenging cancers because of its heterogeneous and aggressive nature, precluding the use of curative treatments. Sorafenib (SOR) is the first approved molecular targeting agent against the mitogen-activated protein kinase (MAPK) pathway for the noncurative therapy of advanced HCC; yet, any clinically meaningful benefits from the treatment remain modest, and are accompanied by significant side effects. Here, we hypothesized that using a nanomedicine platform to co-deliver SOR with another molecular targeting drug, metformin (MET), could tackle these issues. A micelle self-assembled with amphiphilic polypeptide methoxy poly(ethylene glycol)-block-poly(L-phenylalanine-co-l-glutamic acid) (mPEG-b-P(LP-co-LG)) (PM) was therefore designed for combinational delivery of two molecular targeted drugs, SOR and MET, to hepatomas. Compared with free drugs, the proposed, dual drug-loaded micelle (PM/SOR+MET) enhanced the drugs' half-life in the bloodstream and drug accumulation at the tumor site, thereby inhibiting tumor growth effectively in the preclinical subcutaneous, orthotopic and patient-derived xenograft hepatoma models without causing significant systemic and organ toxicity. Collectively, these findings demonstrate an effective dual-targeting nanomedicine strategy for treating advanced HCC, which may have a translational potential for cancer therapeutics. STATEMENT OF SIGNIFICANCE: Treatment of advanced hepatocellular carcinoma (HCC) remains a formidable challenge due to its aggressive nature and the limitations inherent to current therapies. Despite advancements in molecular targeted therapies, such as Sorafenib (SOR), their modest clinical benefits coupled with significant adverse effects underscore the urgent need for more efficacious and less toxic treatment modalities. Our research presents a new nanomedicine platform that synergistically combines SOR with metformin within a specialized diblock polypeptide micelle, aiming to enhance therapeutic efficacy while reducing systemic toxicity. This innovative approach not only exhibits marked antitumor efficacy across multiple HCC models but also significantly reduces the toxicity associated with current treatments. Our dual-molecular targeting approach unveils a promising nanomedicine strategy for the molecular treatment of advanced HCC, potentially offering more effective and safer treatment alternatives with significant translational potential., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
7. Nanosimilars: A Scientific or A Regulatory Debate?
- Author
-
Demetzos C
- Subjects
- Humans, Biosimilar Pharmaceuticals administration & dosage, Biosimilar Pharmaceuticals pharmacokinetics, Artificial Intelligence, Nanoparticles, Drug Industry legislation & jurisprudence, Drug Approval legislation & jurisprudence, Drug Carriers chemistry, Nanomedicine legislation & jurisprudence, Nanomedicine methods
- Abstract
The paper highlights the necessity for a robust regulatory framework for assessing nanomedicines and their off-patent counterparts, termed as nanosimilar, which could be considered as 'similar' to the prototype nanomedicine,based on essential criteria describing the 'similarity'. The term 'similarity' should be focused on criteria that describe nanocarriers, encompassing their physicochemical, thermodynamic, morphological, and biological properties, including surface interactions and pharmacokinetics. Nanocarriers can be regarded as advanced self-assembled excipients (ASAEs) due to their complexity and chaotic behavior and should be evaluated by using essential criteria in order for off-patent nanomedicines be termed as nanosimilars, from a regulatory perspective. Collaboration between the pharmaceutical industry, regulatory bodies, and artificial intelligence (AI) startups is pivotal for the precise characterization and approval processes for nanomedicines and nanosimilars and embracing innovative tools and terminology facilitates the development of a sustainable regulatory framework, ensuring safety and efficacy. This crucial shift toward precision R&D practices addresses the complexity inherent in nanocarriers, paving the way for therapeutic advancements with economic benefits., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
8. Modulating the immune system towards a functional chronic wound healing: A biomaterials and Nanomedicine perspective.
- Author
-
Las Heras K, Garcia-Orue I, Rancan F, Igartua M, Santos-Vizcaino E, and Hernandez RM
- Subjects
- Humans, Animals, Immune System, Nanostructures, Wound Healing drug effects, Wound Healing immunology, Biocompatible Materials, Nanomedicine
- Abstract
Chronic non-healing wounds persist as a substantial burden for healthcare systems, influenced by factors such as aging, diabetes, and obesity. In contrast to the traditionally pro-regenerative emphasis of therapies, the recognition of the immune system integral role in wound healing has significantly grown, instigating an approach shift towards immunological processes. Thus, this review explores the wound healing process, highlighting the engagement of the immune system, and delving into the behaviors of innate and adaptive immune cells in chronic wound scenarios. Moreover, the article investigates biomaterial-based strategies for the modulation of the immune system, elucidating how the adjustment of their physicochemical properties or their synergistic combination with other agents such as drugs, proteins or mesenchymal stromal cells can effectively modulate the behaviors of different immune cells. Finally this review explores various strategies based on synthetic and biological nanostructures, including extracellular vesicles, to finely tune the immune system as natural immunomodulators or therapeutic nanocarriers with promising biophysical properties., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
9. Nanomedicines targeting activated immune cells and effector cells for rheumatoid arthritis treatment.
- Author
-
Deng Y, Zheng H, Li B, Huang F, Qiu Y, Yang Y, Sheng W, Peng C, Tian X, Wang W, and Yu H
- Subjects
- Humans, Animals, Drug Delivery Systems, Antirheumatic Agents administration & dosage, Antirheumatic Agents pharmacology, Antirheumatic Agents therapeutic use, Extracellular Vesicles, Arthritis, Rheumatoid drug therapy, Arthritis, Rheumatoid immunology, Nanomedicine methods, Nanoparticles administration & dosage
- Abstract
Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease characterized by synovial inflammation and inflammatory cellular infiltration. Functional cells in the RA microenvironment (RAM) are composed of activated immune cells and effector cells. Activated immune cells, including macrophages, neutrophils, and T cells, can induce RA. Effector cells, including synoviocytes, osteoclasts, and chondrocytes, receiving inflammatory stimuli, exacerbate RA. These functional cells, often associated with the upregulation of surface-specific receptor proteins and significant homing effects, can secrete pro-inflammatory factors and interfere with each other, thereby jointly promoting the progression of RA. Recently, some nanomedicines have alleviated RA by targeting and modulating functional cells with ligand modifications, while other nanoparticles whose surfaces are camouflaged by membranes or extracellular vesicles (EVs) of these functional cells target and attack the lesion site for RA treatment. When ligand-modified nanomaterials target specific functional cells to treat RA, the functional cells are subjected to attack, much like the intended targets. When functional cell membranes or EVs are modified onto nanomaterials to deliver drugs for RA treatment, functional cells become the attackers, similar to arrows. This study summarized how diversified functional cells serve as targets or arrows by engineered nanoparticles to treat RA. Moreover, the key challenges in preparing nanomaterials and their stability, long-term efficacy, safety, and future clinical patient compliance have been discussed here., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)
- Published
- 2024
- Full Text
- View/download PDF
10. Chitosan nanomedicines-engineered bifidobacteria complexes for effective colorectal tumor-targeted delivery of SN-38.
- Author
-
Wu D, Fu K, Zhang W, Li Y, Ji Y, Dai Y, and Yang G
- Subjects
- Animals, Humans, Drug Liberation, Drug Carriers chemistry, Drug Delivery Systems, Antineoplastic Agents, Phytogenic administration & dosage, Antineoplastic Agents, Phytogenic pharmacology, Mice, Camptothecin administration & dosage, Camptothecin analogs & derivatives, Camptothecin chemistry, Camptothecin pharmacology, Mice, Inbred BALB C, Cell Line, Tumor, Bifidobacterium bifidum, Mice, Nude, Female, Irinotecan administration & dosage, Irinotecan pharmacology, Chitosan chemistry, Colorectal Neoplasms drug therapy, Polyglutamic Acid chemistry, Polyglutamic Acid analogs & derivatives, Nanomedicine methods
- Abstract
The clinical application of 7-ethyl hydroxy-camptothecin (SN-38) maintains challenges not only due to its poor solubility and stability but also the lack of effective carriers to actively deliver SN-38 to deep tumor sites. Although SN-38-based nanomedicines could improve the solubility and stability from different aspects, the tumor targeting efficiency remains very low. Leveraging the hypoxic taxis of bifidobacteria bifidum (B. bifi) to the deep tumor area, we report SN-38-based nanomedicines-engineered bifidobacterial complexes for effective tumor-targeted delivery. Firstly, SN-38 was covalently coupled with poly-L-glutamic acid (L-PGA) and obtained soluble polymeric prodrug L-PGA-SN38 to improve its solubility and stability. To prolong the drug release, L-PGA-SN38 was mildly complexed with chitosan to form nanomedicines, and nanomedicines engineered B. bifi were further elaborated via electrostatic interaction of the excess of cationic chitosan shell from nanomedicines and anionic teichoic acid from B. bifi. The engineered B. bifi complexes inherited the bioactivity of native B. bifi and exhibited distinctly enhanced accumulation at the tumor site. More importantly, significantly elevated anti-tumor efficacy was achieved after the treatment of CS-L-PGA-SN38 NPs/B. bifi complexes, with favorable tumor suppression up to 80%. Such a B. bifi-mediated delivery system offers a promising platform for effective drug delivery and enhanced drug accumulation in the hypoxia deep tumor with superior anti-tumor efficacy., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
11. Diclofenac sodium nanomedicine results in pain-relief and differential expression of the RNA transcriptome in the spinal cord of SNI rats.
- Author
-
Zhang Y, Yang D, Shuai B, Ding H, Yang J, Wang J, Tang L, Yao S, and Zhang Y
- Subjects
- Animals, Male, Rats, Drug Carriers chemistry, Anti-Inflammatory Agents, Non-Steroidal administration & dosage, Anti-Inflammatory Agents, Non-Steroidal pharmacology, Drug Liberation, Delayed-Action Preparations, Disease Models, Animal, Hyperalgesia drug therapy, Diclofenac administration & dosage, Diclofenac pharmacology, Neuralgia drug therapy, Rats, Sprague-Dawley, Spinal Cord metabolism, Spinal Cord drug effects, Transcriptome drug effects, Nanomedicine methods
- Abstract
Neuropathic pain is chronic pain caused by a lesion or disease of the somatosensory nervous system. Neuropathic pain, with a high incidence and complex pathogenesis, is one of the most significant areas of clinical medicine and basic research. Currently, prescribed treatments are still unsatisfactory or have limited effectiveness. A medicinal preparation is required that relieves the neuropathic pain and prolongs action time, which has not yet been discovered. In this study, MIL-101 (Fe) was employed as a drug carrier to regulate the release of diclofenac sodium, thereby achieving the effect of analgesia and sustained release. The release curves demonstrated that diclofenac sodium could be continuously released from MIL-101 (Fe) for more than 48 h. There was no toxicity in vitro and in vivo, and the safety of MIL-101 (Fe) was confirmed by hematoxylin and eosin as well as ELISA tests in vivo. The results of behavioral testing, pharmacokinetics, and RNA sequencing analysis showed that MIL-101 (Fe) loaded with diclofenac sodium could enhance the mechanical withdrawal threshold and alleviate cold allodynia induced by Spared Nerve Injury, prolonging the work time by three days. The results indicated that MIL-101 (Fe) exhibited excellent biocompatibility, while the MIL-101 (Fe)-DS demonstrated analgesic and controlled-release properties. These findings provide a scientific foundation for the clinical management of neuropathic pain and the development of a novel formulation., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
12. Advanced Nanomedicine Approaches for Myocardial Infarction Treatment.
- Author
-
Song L, Jia K, Yang F, and Wang J
- Subjects
- Humans, Animals, Myocytes, Cardiac drug effects, Antioxidants therapeutic use, Nanostructures therapeutic use, Nanostructures chemistry, Neovascularization, Physiologic drug effects, Myocardial Infarction therapy, Nanomedicine
- Abstract
Myocardial infarction, usually caused by the rupture of atherosclerotic plaque, leads to irreversible ischemic cardiomyocyte death within hours followed by impaired cardiac performance or even heart failure. Current interventional reperfusion strategies for myocardial infarction still face high mortality with the development of heart failure. Nanomaterial-based therapy has made great progress in reducing infarct size and promoting cardiac repair after MI, although most studies are preclinical trials. This review focuses primarily on recent progress (2016-now) in the development of various nanomedicines in the treatment of myocardial infarction. We summarize these applications with the strategy of mechanism including anti-cardiomyocyte death strategy, activation of neovascularization, antioxidants strategy, immunomodulation, anti-cardiac remodeling, and cardiac repair., Competing Interests: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (© 2024 Song et al.)
- Published
- 2024
- Full Text
- View/download PDF
13. Mechanisms and Barriers in Nanomedicine: Progress in the Field and Future Directions.
- Author
-
Anchordoquy T, Artzi N, Balyasnikova IV, Barenholz Y, La-Beck NM, Brenner JS, Chan WCW, Decuzzi P, Exner AA, Gabizon A, Godin B, Lai SK, Lammers T, Mitchell MJ, Moghimi SM, Muzykantov VR, Peer D, Nguyen J, Popovtzer R, Ricco M, Serkova NJ, Singh R, Schroeder A, Schwendeman AA, Straehla JP, Teesalu T, Tilden S, and Simberg D
- Subjects
- Humans, Drug Carriers chemistry, Liposomes chemistry, Nanoparticles chemistry, United States, Nanomedicine
- Abstract
In recent years, steady progress has been made in synthesizing and characterizing engineered nanoparticles, resulting in several approved drugs and multiple promising candidates in clinical trials. Regulatory agencies such as the Food and Drug Administration and the European Medicines Agency released important guidance documents facilitating nanoparticle-based drug product development, particularly in the context of liposomes and lipid-based carriers. Even with the progress achieved, it is clear that many barriers must still be overcome to accelerate translation into the clinic. At the recent conference workshop "Mechanisms and Barriers in Nanomedicine" in May 2023 in Colorado, U.S.A., leading experts discussed the formulation, physiological, immunological, regulatory, clinical, and educational barriers. This position paper invites open, unrestricted, nonproprietary discussion among senior faculty, young investigators, and students to trigger ideas and concepts to move the field forward.
- Published
- 2024
- Full Text
- View/download PDF
14. Efficient computational model of the in-flow capturing of magnetic nanoparticles by a cylindrical magnet for cancer nanomedicine.
- Author
-
Wirthl B, Wirthl V, and Wall WA
- Subjects
- Magnets chemistry, Humans, Neoplasms therapy, Nanomedicine, Magnetite Nanoparticles chemistry, Computer Simulation
- Abstract
Magnetic nanoparticles have emerged as a promising approach to improving cancer treatment. However, many nanoparticle designs fail in clinical trials due to a lack of understanding of how to overcome the in vivo transport barriers. To address this shortcoming, we develop a computational model aimed at the study of magnetic nanoparticles in vitro and in vivo. In this paper, we present an important building block for this overall goal, namely an efficient computational model of the in-flow capture of magnetic nanoparticles by a cylindrical permanent magnet in an idealized test setup. We use a continuum approach based on the Smoluchowski advection-diffusion equation, combined with a simple approach to consider the capture at an impenetrable boundary, and derive an analytical expression for the magnetic force of a cylindrical magnet of finite length on the nanoparticles. This provides a simple and numerically efficient way to study different magnet configurations and their influence on the nanoparticle distribution in three dimensions. Such an in silico model can increase insight into the underlying physics, help to design prototypes, and serve as a precursor to more complex systems in vivo and in silico.
- Published
- 2024
- Full Text
- View/download PDF
15. The biomolecular corona of nanomedicines: effects on nanomedicine outcomes and emerging opportunities.
- Author
-
Salvati A
- Subjects
- Humans, Nanoparticles chemistry, Animals, Nanomedicine methods, Protein Corona chemistry, Protein Corona metabolism
- Abstract
Upon administration, nanomedicines adsorb a corona of endogenous biomolecules on their surface, which can affect nanomedicine interactions with cells, targeting, and efficacy. While strategies to reduce protein binding are available, the high selectivity of the adsorbed corona is enabling novel applications, such as for biomarker discovery and rare protein identification. Additionally, the adsorbed molecules can promote interactions with specific cell receptors, thus conferring the nanomedicine new endogenous targeting capabilities. This has been reported for Onpattro, a lipid nanoparticle targeting the hepatocytes via apolipoproteins in its corona. Recently, selective organ-targeting (SORT) nanoparticles have been proposed, which exploit corona-mediated interactions to deliver nanoparticles outside the liver. Strategies for corona seeding and corona engineering are emerging to increase the selectivity of similar endogenous targeting mechanisms., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
16. The role of CCL2/CCR2 axis in cancer and inflammation: The next frontier in nanomedicine.
- Author
-
Pozzi S and Satchi-Fainaro R
- Subjects
- Humans, Animals, Tumor Microenvironment drug effects, Antineoplastic Agents therapeutic use, Antineoplastic Agents pharmacology, Antineoplastic Agents administration & dosage, Drug Delivery Systems, Receptors, CCR2 antagonists & inhibitors, Receptors, CCR2 metabolism, Neoplasms drug therapy, Neoplasms metabolism, Neoplasms pathology, Inflammation drug therapy, Inflammation metabolism, Chemokine CCL2 metabolism, Chemokine CCL2 antagonists & inhibitors, Nanomedicine
- Abstract
The communication between cells and their microenvironment represents an intrinsic and essential attribute that takes place in several biological processes, including tissue homeostasis and tissue repair. Among these interactions, inflammation is certainly a central biological response that occurs through cytokines and the crosstalk with their respective receptors. In particular, the interaction between CCL2 and its main receptor, CCR2, plays a pivotal role in both harmful and protective inflammatory states, including cancer-mediated inflammation. The activation of the CCL2/CCR2 axis was shown to dictate the migration of macrophages with immune-suppressive phenotype and to aggravate the progression of different cancer types. In addition, this interaction mediates metastasis formation, further limiting the potential therapeutic outcome of anti-cancer drugs. Attempts to inhibit pharmacologically the CCL2/CCR2 axis have yet to show its anti-cancer efficacy as a single agent, but it sheds light on its role as a powerful tool to selectively alleviate pro-tumorigenic and anti-repair inflammation. In this review, we will elucidate the role of CCL2/CCR2 axis in promoting cancer inflammation by activating the host pro-tumorigenic phenotype. Moreover, we will provide some insight into the potential therapeutic benefit of targeting the CCL2/CCR2 axis for cancer and inflammation using novel delivery systems, aiming to sensitize non-responders to currently approved immunotherapies and offer new combinatory approaches., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
17. EGCG-vanadium nanomedicine with neutral pH Fenton reaction activity inhibits heat shock proteins for enhanced photothermal/chemodynamic therapy.
- Author
-
Wang R, Cao HC, Yang Q, Wei S, Liu T, and Shi H
- Subjects
- Hydrogen-Ion Concentration, Animals, Humans, Mice, Photothermal Therapy methods, Vanadium chemistry, Vanadium pharmacology, Cell Line, Tumor, Neoplasms drug therapy, Neoplasms therapy, Neoplasms pathology, Hydrogen Peroxide, Catechin analogs & derivatives, Catechin chemistry, Catechin pharmacology, Nanomedicine methods, Heat-Shock Proteins metabolism
- Abstract
A burgeoning interest has recently focused on the development of nanomedicine to integrate noninvasive photothermal therapy (PTT) and chemodynamic therapy (CDT) for synergistic tumor treatments, owing to PTT's amplification effect on CDT. However, challenges emerge as hyperthermia often induces an unwarranted overexpression of cytoprotective heat shock proteins (HSPs), thereby curtailing PTT efficacy. Additionally, the nearly neutral tumor intracellular pH (pH
i ≈ 7.2) that handicaps the Fenton reaction poses a leading limitation to CDT. Addressing these hurdles, we introduce EVP, a nanomedicine developed through the straightforward assembly of epigallocatechin gallate (EGCG), vanadium sulfate (VOSO4 ), and Pluronic F-127 (PF127). EVP comprehensively downregulates overexpressed HSPs (HSP 60, 70, 90) through the collaborative action of EGCG and vanadyl (VO2+ ). Moreover, the tumor intracellular pH-processed Fenton-like reaction by VO2+ ensures highly efficient hydroxyl radicals (OH) production in cytosols, overcoming the stringent acidity requirement for CDT. Additionally, the hyperthermia induced by PTT augments OH production, further enhancing CDT efficacy. In vitro and in vivo experiments validate EVP's excellent biocompatibility and potent tumor inhibition, highlighting its substantial potential in tumor therapy., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024. Published by Elsevier B.V.)- Published
- 2024
- Full Text
- View/download PDF
18. Nanomedicine biointeractions during body trafficking.
- Author
-
He W, Gao H, and Wu W
- Subjects
- Humans, Drug Delivery Systems, Biological Transport, Nanomedicine
- Abstract
Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2024
- Full Text
- View/download PDF
19. Novel therapeutic perspectives for wet age-related macular degeneration: RGD-modified liposomes loaded with 2-deoxy-D-glucose as a promising nanomedicine.
- Author
-
Chen X, Liu S, Chen M, Ni N, Zhou R, Wang Y, Xu Y, Wang Y, Gao H, Zhang D, Tang Z, Shu Q, Zhang J, Li L, Ju Y, and Gu P
- Subjects
- Animals, Humans, Human Umbilical Vein Endothelial Cells metabolism, Human Umbilical Vein Endothelial Cells drug effects, Mice, Mice, Inbred C57BL, Endothelial Cells drug effects, Endothelial Cells metabolism, Liposomes, Oligopeptides chemistry, Nanomedicine methods, Choroidal Neovascularization drug therapy, Choroidal Neovascularization pathology, Choroidal Neovascularization metabolism, Wet Macular Degeneration drug therapy, Wet Macular Degeneration metabolism, Deoxyglucose pharmacology, Deoxyglucose administration & dosage, Vascular Endothelial Growth Factor Receptor-2 metabolism
- Abstract
Choroidal neovascularization (CNV), characterized as a prominent feature of wet age-related macular degeneration (AMD), is a primary contributor to visual impairment and severe vision loss globally, while the prevailing treatments are often unsatisfactory. The development of conventional treatment strategies has largely been based on the understanding that the angiogenic switch of endothelial cells is dictated by angiogenic growth factors alone. Even though treatments targeting vascular endothelial growth factor (VEGF), like Ranibizumab, are widely administered, more than half of the patients still exhibit inadequate or null responses, emphasizing the imperative need for solutions to this problem. Here, aiming to explore therapeutic strategies from a novel perspective of endothelial cell metabolism, a biocompatible nanomedicine delivery system is constructed by loading RGD peptide-modified liposomes with 2-deoxy-D-glucose (RGD@LP-2-DG). RGD@LP-2-DG displayed good targeting performance towards endothelial cells and excellent in vitro and in vivo inhibitory effects on neovascularization were demonstrated. Moreover, our mechanistic studies revealed that 2-DG interfered with N-glycosylation, leading to the inhibition of vascular endothelial growth factor receptor 2 (VEGFR2) and its downstream signaling. Notably, the remarkable inhibitory effect on neovascularization and biocompatibility of RGD@LP-2-DG render it a highly promising and clinically translatable therapeutic candidate for the treatment of wet AMD and other angiogenic diseases, particularly in patients who are unresponsive to currently available treatments., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
20. Precision nanomedicine to treat non-small cell lung cancer.
- Author
-
Dessai A, Nayak UY, and Nayak Y
- Subjects
- Humans, Nanoparticles chemistry, Animals, Antineoplastic Agents therapeutic use, Antineoplastic Agents administration & dosage, Carcinoma, Non-Small-Cell Lung drug therapy, Lung Neoplasms drug therapy, Precision Medicine methods, Nanomedicine methods
- Abstract
Lung cancer is a major cause of death worldwide, being often detected at a later stage due to the non-appearance of early symptoms. Therefore, specificity of the treatment is of utmost importance for its effective treatment. Precision medicine is a personalized therapy based on the genomics of the patient to design a suitable drug approach. Genetic mutations render the tumor resistant to specific mutations and the therapy is in vain even though correct medications are prescribed. Therefore, Precision medicine needs to be explored for the treatment of Non-small cell lung cancer (NSCLC). Nanoparticles are widely explored to give personalized interventions to treat lung cancer due to their various advantages like the ability to reach cancer cells, enhanced permeation through tissues, specificity, increased bioavailability, etc. Various nanoparticles (NPs) including gold nanoparticles, carbon nanotubes, aptamer-based NPs etc. were conjugated with biomarkers/diagnostic agents specific to cancer type and were delivered. Various biomarker genes have been identified through precision techniques for the diagnosis and treatment of NSCLC like EGFR, RET, KRAS, ALK, ROS-1, NTRK-1, etc. By incorporating of drug with the nanoparticle through bioconjugation, the specificity of the treatment can be enhanced with this revolutionary treatment. Additionally, integration of theranostic cargos in the nanoparticle would allow diagnosis as well as treatment by targeting the site of disease progression. Therefore, to target NSCLC effectively precision nanomedicine has been adopted in recent times. Here, we present different nanoparticles that are used as precision nanomedicine and their effectiveness against NSCLC disease., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
21. Superior Drug Delivery Performance of Multifunctional Bilosomes: Innovative Strategy to Kill Skin Cancer Cells for Nanomedicine Application.
- Author
-
Waglewska E, Kulbacka J, and Bazylinska U
- Subjects
- Humans, Cell Line, Tumor, Cell Survival drug effects, Liposomes chemistry, Liposomes pharmacology, Cholesterol chemistry, Phosphatidylcholines chemistry, Phosphatidylcholines pharmacology, Sodium Cholate chemistry, Drug Delivery Systems methods, Poloxalene chemistry, Poloxalene pharmacology, Skin Neoplasms drug therapy, Melanoma drug therapy, Photochemotherapy methods, Photosensitizing Agents pharmacology, Photosensitizing Agents chemistry, Photosensitizing Agents administration & dosage, Curcumin chemistry, Curcumin pharmacology, Nanomedicine
- Abstract
Purpose: Numerous failures in melanoma treatment as a highly aggressive form of skin cancer with an unfavorable prognosis and excessive resistance to conventional therapies are prompting an urgent search for more effective therapeutic tools. Consequently, to increase the treatment efficiency and to reduce the side effects of traditional administration ways, herein, it has become crucial to combine photodynamic therapy as a promising therapeutic approach with the selectivity and biocompatibility of a novel colloidal transdermal nanoplatform for effective delivery of hybrid cargo with synergistic effects on melanoma cells., Methods: The self-assembled bilosomes, co-stabilized with L-α-phosphatidylcholine, sodium cholate, Pluronic
® P123, and cholesterol, were designated, and the stability of colloidal vesicles was studied using dynamic and electrophoretic light scattering, also provided in cell culture medium (Dulbecco's Modified Eagle's Medium). The hybrid compounds - a classical photosensitizer (Methylene Blue) along with a complementary natural polyphenolic agent (curcumin), were successfully co-loaded, as confirmed by UV-Vis, ATR-FTIR, and fluorescent spectroscopies. The biocompatibility and usefulness of the polymer functionalized bilosome with loaded double cargo were demonstrated in vitro cyto- and phototoxicity experiments using normal keratinocytes and melanoma cancer cells., Results: The in vitro bioimaging and immunofluorescence study upon human skin epithelial (A375) and malignant (Me45) melanoma cell lines established the protective effect of the PEGylated bilosome surface. This effect was confirmed in cytotoxicity experiments, also determined on human cutaneous (HaCaT) keratinocytes. The flow cytometry experiments indicated the enhanced uptake of the encapsulated hybrid cargo compared to the non-loaded MB and CUR molecules, as well as a selectivity of the obtained nanocarriers upon tumor cell lines. The phyto-photodynamic action provided 24h-post irradiation revealed a more significant influence of the nanoplatform on Me45 cells in contrast to the A375 cell line, causing the cell viability rate below 20% of the control., Conclusion: As a result, we established an innovative and effective strategy for potential metastatic melanoma treatment through the synergism of phyto-photodynamic therapy and novel bilosomal-origin nanophotosensitizers., Competing Interests: The authors of this paper declare no competing financial or other interests that could affect the work they describe here., (© 2024 Waglewska et al.)- Published
- 2024
- Full Text
- View/download PDF
22. Comment on "Nanomedicine, an emerging therapeutic strategy for oral cancer therapy".
- Author
-
Saravanan M
- Subjects
- Humans, Mouth Neoplasms therapy, Mouth Neoplasms drug therapy, Nanomedicine methods
- Abstract
Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
- Published
- 2024
- Full Text
- View/download PDF
23. Nanomedicine revolutionizes epilepsy treatment: overcoming therapeutic hurdles with nanoscale solutions.
- Author
-
Li S, Zhang W, Zhu Y, Yao Q, Chen R, Kou L, and Shi X
- Subjects
- Humans, Animals, Nanoparticles, Solubility, Drug Stability, Nanomedicine methods, Epilepsy drug therapy, Anticonvulsants administration & dosage, Anticonvulsants therapeutic use, Drug Delivery Systems, Blood-Brain Barrier metabolism
- Abstract
Introduction: Epilepsy, a prevalent neurodegenerative disorder, profoundly impacts the physical and mental well-being of millions globally. Historically, antiseizure drugs (ASDs) have been the primary treatment modality. However, despite the introduction of novel ASDs in recent decades, a significant proportion of patients still experiences uncontrolled seizures., Areas Covered: The rapid advancement of nanomedicine in recent years has enabled precise targeting of the brain, thereby enhancing therapeutic efficacy for brain diseases, including epilepsy., Expert Opinion: Nanomedicine holds immense promise in epilepsy treatment, including but not limited to enhancing drug solubility and stability, improving drug across blood-brain barrier, overcoming resistance, and reducing side effects, potentially revolutionizing clinical management. This paper provides a comprehensive overview of current epilepsy treatment modalities and highlights recent advancements in nanomedicine-based drug delivery systems for epilepsy control. We discuss the diverse strategies used in developing novel nanotherapies, their mechanisms of action, and the potential advantages they offer compared to traditional treatment methods.
- Published
- 2024
- Full Text
- View/download PDF
24. Regulatory insights into nanomedicine and gene vaccine innovation: Safety assessment, challenges, and regulatory perspectives.
- Author
-
Souto EB, Blanco-Llamero C, Krambeck K, Kiran NS, Yashaswini C, Postwala H, Severino P, Priefer R, Prajapati BG, and Maheshwari R
- Subjects
- Humans, Vaccines, DNA adverse effects, Nanomedicine
- Abstract
This analysis explores the principal regulatory concerns linked to nanomedicines and gene vaccines, including the complexities involved and the perspectives on how to navigate them. In the realm of nanomedicines, ensuring the safety of nanomaterials is paramount due to their unique characteristics and potential interactions with biological systems. Regulatory bodies are actively formulating guidelines and standards to assess the safety and risks associated with nanomedicine products, emphasizing the need for standardized characterization techniques to accurately gauge their safety and effectiveness. Regarding gene vaccines, regulatory frameworks must be tailored to address the distinct challenges posed by genetic interventions, necessitating special considerations in safety and efficacy evaluations, particularly concerning vector design, target specificity, and long-term patient monitoring. Ethical concerns such as patient autonomy, informed consent, and privacy also demand careful attention, alongside the intricate matter of intellectual property rights, which must be balanced against the imperative of ensuring widespread access to these life-saving treatments. Collaborative efforts among regulatory bodies, researchers, patent offices, and the private sector are essential to tackle these challenges effectively, with international cooperation being especially crucial given the global scope of nanomedicine and genetic vaccine development. Striking the right balance between safeguarding intellectual properties and promoting public health is vital for fostering innovation and ensuring equitable access to these ground-breaking technologies, underscoring the significance of addressing these regulatory hurdles to fully harness the potential benefits of nanomedicine and gene vaccines for enhancing healthcare outcomes on a global scale. STATEMENT OF SIGNIFICANCE: Several biomaterials are being proposed for the development of nanovaccines, from polymeric micelles, PLGA-/PEI-/PLL-nanoparticles, solid lipid nananoparticles, cationic lipoplexes, liposomes, hybrid materials, dendrimers, carbon nanotubes, hydrogels, to quantum dots. Lipid nanoparticles (LNPs) have gained tremendous attention since the US Food and Drug Administration (FDA) approval of Pfizer and Moderna's COVID-19 vaccines, raising public awareness to the regulatory challenges associated with nanomedicines and genetic vaccines. This review provides insights into the current perspectives and potential strategies for addressing these issues, including clinical trials. By navigating these regulatory landscapes effectively, we can unlock the full potential of nanomedicine and genetic vaccines using a range of promising biomaterials towards improving healthcare outcomes worldwide., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Author(s). Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. Emerging application of nanomedicine-based therapy in acute respiratory distress syndrome.
- Author
-
Xu Y, Lv L, Wang Q, Yao Q, Kou L, and Zhang H
- Subjects
- Humans, Lung, Drug Delivery Systems, Nanomedicine, Respiratory Distress Syndrome drug therapy
- Abstract
Acute lung injury (ALI) and acute respiratory distress syndrome (ARDS) are serious lung injuries caused by various factors, leading to increased permeability of the alveolar-capillary barrier, reduced stability of the alveoli, inflammatory response, and hypoxemia. Despite several decades of research since ARDS was first formally described in 1967, reliable clinical treatment options are still lacking. Currently, supportive therapy and mechanical ventilation are prioritized, and there is no medication that can be completely effective in clinical treatment. In recent years, nanomedicine has developed rapidly and has exciting preclinical treatment capabilities. Using a drug delivery system based on nanobiotechnology, local drugs can be continuously released in lung tissue at therapeutic levels, reducing the frequency of administration and improving patient compliance. Furthermore, this novel drug delivery system can target specific sites and reduce systemic side effects. Currently, many nanomedicine treatment options for ARDS have demonstrated efficacy. This review briefly introduces the pathophysiology of ARDS, discusses various research progress on using nanomedicine to treat ARDS, and anticipates future developments in related fields., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Declaration of Competing Interest The authors confirm that there are no conflicts of interest., (Copyright © 2024 Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
26. Colorectal cancer: a comprehensive review of carcinogenesis, diagnosis, and novel strategies for classified treatments
- Author
-
Abedizadeh, Roya, Majidi, Fateme, Khorasani, Hamid Reza, Abedi, Hassan, and Sabour, Davood
- Published
- 2024
- Full Text
- View/download PDF
27. Contents list.
- Subjects
PERSPIRATION ,LABS on a chip ,NANOMEDICINE ,GOLD nanoparticles ,ENTEROHEPATIC circulation ,ERYTHROCYTE membranes ,POROUS materials ,MICROFLUIDIC devices ,ERYTHROCYTES - Published
- 2024
- Full Text
- View/download PDF
28. Immunomodulatory nanomedicine for osteoporosis: Current practices and emerging prospects.
- Author
-
Luo Y, Liu H, Chen M, Zhang Y, Zheng W, Wu L, Liu Y, Liu S, Luo E, and Liu X
- Subjects
- Humans, Animals, Osteogenesis drug effects, Immunomodulation drug effects, Osteoporosis drug therapy, Nanomedicine methods
- Abstract
Osteoporosis results from the disruption of the balance between bone resorption and bone formation. However, classical anti-osteoporosis drugs exhibit several limitations in clinical applications, such as multiple adverse reactions and poor therapeutic effects. Therefore, there is an urgent need for alternative treatment strategies. With the evolution of immunomodulatory nanomedicine, a variety of nanomaterials have been designed for anti-osteoporosis treatment, offering prospects of minimal adverse reactions, enhanced bone induction, and high osteogenic activity. This review initially provides a brief overview of the fundamental principles of bone reconstruction, current osteogenic clinical methods in osteoporosis treatment, and the significance of osteogenic-angiogenic coupling, laying the groundwork for understanding the pathophysiology and therapeutics of osteoporosis. Subsequently, the article emphasizes the relationship between bone immunity and osteogenesis-angiogenesis coupling and provides a detailed analysis of the application of immunomodulatory nanomedicines in the treatment of osteoporosis, including various types of nanomaterials and their integration with carrier biomaterials. Importantly, we discuss the potential of some emerging strategies in immunomodulatory nanomedicine for osteoporosis treatment. This review introduces the innovative applications of immunomodulatory nanomedicine in the treatment of osteoporosis, aiming to serve as a reference for the application of immunomodulatory nanomedicine strategies in osteoporosis treatment. STATEMENT OF SIGNIFICANCE: Osteoporosis, as one of the most prevalent skeletal disorders, poses a significant threat to public health. To date, conventional anti-osteoporosis strategies have been limited in efficacy and plagued with numerous side effects. Fortunately, with the advancement of research in osteoimmunology and nanomedicine, strategies integrating these two fields show great promise in combating osteoporosis. Nanomedicine with immunomodulatory properties exhibits enhanced efficiency, prolonged effectiveness, and increased safety. However, as of now, there exists no comprehensive review amalgamating immunomodulation with nanomedicine to delineate the progress of immunomodulatory nanomedicine in osteoporosis treatment, as well as the future direction of this strategy., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
29. A nanomedicine composed of polymer-ss-DOX and polymer-Ce6 prodrugs with monoclonal antibody targeting effect for anti-tumor chemo-photodynamic synergetic therapy.
- Author
-
Yu L, Zhang M, He J, Sun X, and Ni P
- Subjects
- Animals, Cell Line, Tumor, Humans, Antineoplastic Agents pharmacology, Antineoplastic Agents chemistry, Antibodies, Monoclonal pharmacology, Antibodies, Monoclonal chemistry, Antibodies, Monoclonal pharmacokinetics, Mice, Polymers chemistry, Polymers pharmacology, Mice, Inbred BALB C, Polyethylene Glycols chemistry, Polyethylene Glycols pharmacology, Apoptosis drug effects, Prodrugs pharmacology, Prodrugs chemistry, Prodrugs pharmacokinetics, Doxorubicin pharmacology, Doxorubicin chemistry, Photochemotherapy methods, Chlorophyllides, Nanomedicine methods, Porphyrins chemistry, Porphyrins pharmacology, Porphyrins pharmacokinetics, Micelles
- Abstract
Anticancer drugs used for systemic chemotherapy often exhibit off-target toxicity and uncontrolled drug release due to their lack of targeting. To improve the bioavailability of drugs and reduce side effects, we have developed a mixed micelle of nanomedicine composed of two prodrugs with surface modified monoclonal antibody for cancer therapy. In this system, Nimotuzumab was used as targeting ligands of the mixed micelles (named as DCMMs) that is composed of polymer-doxorubicin prodrug (abbreviated as PEG-b-P(GMA-ss-DOX)) and maleimide polyethylene glycol-chlorin e6 (abbreviated as Mal-PEG-Ce6). The mixed micelles modified with Nimotuzumab (named as NTZ-DCMMs) bind to overexpressed EGFR receptors on Hepatoma-22 (H22) cells. Disulfide bonds in PEG-b-P(GMA-ss-DOX) are disrupted in tumor microenvironment, inducing the reduction-responsive release of DOX and leading to tumor cell apoptosis. Simultaneously, Chlorin e6 (Ce6) produced plenty of singlet oxygen (
1 O2 ) under laser irradiation to kill tumor cells. In vivo biological distribution and antineoplastic effect experiments demonstrate that NTZ-DCMMs enhanced drug enrichment at tumor sites through targeting function of antibody, dramatically suppressing tumor growth and mitigating cardiotoxicity of drugs. All results prove that NTZ-DCMMs have the ability to actively target H22 cells and quickly respond to tumor microenvironment, which is expected to become an intelligent and multifunctional drug delivery carrier for efficient chemotherapy and photodynamic therapy of hepatoma. STATEMENT OF SIGNIFICANCE: Anticancer drugs used for systemic chemotherapy often exhibit off-target toxicity due to their lack of targeting. Therefore, it's necessary to develop effective, targeted, and collaborative treatment strategies. We construct a mixed micelle of nanomedicine based on two polymer prodrugs and modified with monoclonal antibody on surface for cancer therapy. Under the tumor cell microenvironment, the disulfide bonds of polymer-ss-DOX were broken, effectively triggering DOX release. The photosensitizer Ce6 could generate a large amount of ROS under light, which synergistically promotes tumor cell apoptosis. By coupling antibodies to the hydrophilic segments of polymer micelles, drugs can be specifically delivered. Compared with monotherapy, the combination of chemotherapy and photodynamic therapy can significantly enhance the therapeutic effect of liver cancer., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.)- Published
- 2024
- Full Text
- View/download PDF
30. Polyethylene glycol (PEG) as a broad applicability marker for LC-MS/MS-based biodistribution analysis of nanomedicines.
- Author
-
Hyldbakk A, Hansen T, Hak S, and Borgos SEF
- Subjects
- Rats, Animals, Tissue Distribution, Chromatography, Liquid, Tandem Mass Spectrometry, Polyethylene Glycols chemistry, Liquid Chromatography-Mass Spectrometry, Nanomedicine, Cyanoacrylates
- Abstract
Polyethylene glycol (PEG) conjugation (PEGylation) is a well-established strategy to improve the pharmacokinetic and biocompatibility properties of a wide variety of nanomedicines and therapeutic peptides and proteins. This broad use makes PEG an attractive 'allround' candidate marker for the biodistribution of such PEGylated compounds. This paper presents the development of a novel strategy for PEG quantification in biological matrices. The methodology is based on sample hydrolysis which both decomposes the sample matrix and degrades PEGylated analytes to specific molecular fragments more suitable for detection by LC-MS/MS. Method versatility was demonstrated by applying it to a wide variety of PEGylated compounds, including polymeric poly(ethylbutyl cyanoacrylate) (PEBCA) nanoparticles, lipidic nanoparticles (Doxil®, LipImage 815™ and lipid nanoparticles for nucleic acid delivery) and the antibody Cimzia®. Method applicability was assessed by analyzing plasma and tissue samples from a comprehensive drug biodistribution study in rats, of both PEBCA and LipImage 815™ nanoparticles. The results demonstrated the method's utility for biodistribution studies on PEG. Importantly, by using the method described herein in tandem with quantification of nanoparticle payloads, we showed that this approach can provide detailed understanding of various critical aspects of the in vivo behavior of PEGylated nanomedicines, such as drug release and particle stability. Together, the presented results demonstrate the novel method as a robust, versatile and generic approach for biodistribution analysis of PEGylated therapeutics., Competing Interests: Declaration of competing interest The authors declare no competing interests., (Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
31. Applying artificial intelligence and computational modeling to nanomedicine.
- Author
-
Hamilton S and Kingston BR
- Subjects
- Artificial Intelligence, Computer Simulation, Drug Delivery Systems, Nanomedicine methods, Nanoparticles
- Abstract
Achieving specific and targeted delivery of nanomedicines to diseased tissues is a major challenge. This is because the process of designing, formulating, testing, and selecting a nanoparticle delivery vehicle for a specific disease target is governed by complex multivariate interactions. Computational modeling and artificial intelligence are well-suited for analyzing and modeling large multivariate datasets in short periods of time. Computational approaches can be applied to help design nanomedicine formulations, interpret nanoparticle-biological interactions, and create models from high-throughput screening techniques to improve the selection of the ideal nanoparticle carrier. In the future, many steps in the nanomedicine development process will be done computationally, reducing the number of experiments and time needed to select the ideal nanomedicine formulation., Competing Interests: Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
32. Nano-based drug delivery systems for active ingredients from traditional Chinese medicine: Harnessing the power of nanotechnology.
- Author
-
Yong-Bo Zhang, Jun-Fang Wang, Mei-Xia Wang, Jing Peng, Xiang-De Kong, and Jie Tian
- Subjects
NANOMEDICINE ,CHINESE medicine ,DRUG delivery systems ,NANOTECHNOLOGY ,TREATMENT effectiveness ,NATURAL products - Abstract
Introduction: Traditional Chinese medicine (TCM) is gaining worldwide popularity as a complementary and alternativemedicine. The isolation and characterization of active ingredients fromTCMhas become optional strategies for drug development. In order to overcome the inherent limitations of these natural products such as poor water solubility and low bioavailability, the combination of nanotechnology with TCM has been explored. Taking advantage of the benefits offered by the nanoscale, various drug delivery systems have been designed to enhance the efficacy of TCM in the treatment and prevention of diseases. Methods: The manuscript aims to present years of research dedicated to the application of nanotechnology in the field of TCM. Results: The manuscript discusses the formulation, characteristics and therapeutic effects of nano-TCM. Additionally, the formation of carrier-free nanomedicines through self-assembly between active ingredients of TCM is summarized. Finally, the paper discusses the safety behind the application of nano-TCM and proposes potential research directions. Discussion: Despite some achievements, the safety of nano-TCM still need special attention. Furthermore, exploring the substance basis of TCM formulas from the perspective of nanotechnology may provide direction for elucidating the scientific intension of TCM formulas. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
33. Investigating the Research Path from the Past to the Future of the Common Field of Nanotechnology and Fungi: A Bibliometric Study.
- Author
-
Hamayeli, Homa, Mohammadi, Ali, and Ebrahim, Nader Ale
- Subjects
- *
BIBLIOMETRICS , *FUNGI , *NANOTECHNOLOGY , *BIBLIOGRAPHY , *DATABASES , *NANOBIOTECHNOLOGY , *NANOMEDICINE - Abstract
Nanoparticles have been considered in many fields such as medicine and industry due to their very small size and their special physicochemical properties. Biosynthesis of nanoparticles has advantages over other methods. This paper examines the bibliography of the relationship between nanotechnology and fungi from 1985 to 2021. Data were collected from three databases consisting of Web of Science, Scopus, and Dimensions. The number and type of documents were examined and then the analysis was continued using VOSviewer and Bibliometrix-package on the documents of the Scopus database. Analysis of 1203 documents from this database showed an upward trend in the publication in recent years. The term "Fungi" was also identified as the keyword index and India as the country with the most published documents. Future research is likely to be on using modern techniques in the study of nanoparticles as well as focusing on other genera of fungi. This paper explores the relationship between nanotechnology and fungi from 1985 to 2021. Biosynthesis offers advantages in creating nanoparticles, which are tiny particles with unique properties used in many fields. Data from three databases were analysed, indicating an increasing trend in publications in recent years. Future research is likely to focus on modern techniques to study nanoparticles and other types of fungi. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
34. Effect of Digital Therapeutics on Range of Motion, Flexibility, Dynamic Balance, Satisfaction, and Adherence: A Randomized Controlled Trial.
- Author
-
Lee, Su-Ji, Kim, Ji-Won, Lee, Dong-Yeop, Hong, Ji-Heon, Yu, Jae-Ho, Kim, Jin-Seop, Kim, Seong-Gil, and Nam, Yeon-Gyo
- Subjects
DYNAMIC balance (Mechanics) ,SATISFACTION ,CALF muscles ,RANGE of motion of joints ,RANDOMIZED controlled trials ,VIDEO recording ,NANOMEDICINE - Abstract
This study investigated the effect of digital therapeutics on ROM, flexibility, dynamic balance, satisfaction, and adherence. A sample of 34 volunteers was randomly assigned into a Digital Therapeutic Group (DTG) (n = 17) and a Non-Digital Therapeutic Group (NDG) (n = 17). The groups performed four calf muscle stretches and two hamstring stretches for 4 weeks. Flexibility and balance were evaluated to assess the effectiveness of the exercise program. A survey was conducted to assess subjects' satisfaction, and exercise performance record papers and video records were assessed for exercise adherence. The paired t-test was used to compare the two populations before and after the program. The independent t-test was used to compare the change scores between groups. In the pre- and post-comparison within each group, the DTG group showed significant differences in all items except the dorsiflexion range of motion (ROM) (p < 0.05). The left straight leg raise (SLR) was significantly different (p < 0.05), and there was a significant difference in exercise satisfaction and participation between the two groups (p < 0.05). DTG showed improved flexibility, dynamic balance, and higher exercise satisfaction and adherence than NDG. The application, providing lower extremity stretching, can improve dorsiflexion ROM, flexibility of the lower extremity, dynamic balance, exercise satisfaction, and exercise adherence. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
35. Advances in the treatment of atherosclerosis with ligand‐modified nanocarriers.
- Author
-
Deng, Xiujiao, Wang, Jinghao, Yu, Shanshan, Tan, Suiyi, Yu, Tingting, Xu, Qiaxin, Chen, Nenghua, Zhang, Siqi, Zhang, Ming‐Rong, Hu, Kuan, and Xiao, Zeyu
- Subjects
ATHEROSCLEROSIS ,NANOCARRIERS ,NANOPARTICLES ,NANOMEDICINE ,WELL-being - Abstract
Atherosclerosis, a chronic disease associated with metabolism, poses a significant risk to human well‐being. Currently, existing treatments for atherosclerosis lack sufficient efficiency, while the utilization of surface‐modified nanoparticles holds the potential to deliver highly effective therapeutic outcomes. These nanoparticles can target and bind to specific receptors that are abnormally over‐expressed in atherosclerotic conditions. This paper reviews recent research (2018–present) advances in various ligand‐modified nanoparticle systems targeting atherosclerosis by specifically targeting signature molecules in the hope of precise treatment at the molecular level and concludes with a discussion of the challenges and prospects in this field. The intention of this review is to inspire novel concepts for the design and advancement of targeted nanomedicines tailored specifically for the treatment of atherosclerosis. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
36. Nanoformulations in Pharmaceutical and Biomedical Applications: Green Perspectives.
- Author
-
Petrovic, Sanja, Bita, Bogdan, and Barbinta-Patrascu, Marcela-Elisabeta
- Subjects
MATERIALS science ,BIOMIMETICS ,NATURAL resources ,SUSTAINABLE design ,THREE-dimensional printing ,NANOMEDICINE ,ITRACONAZOLE ,DRUG delivery systems - Abstract
This study provides a brief discussion of the major nanopharmaceuticals formulations as well as the impact of nanotechnology on the future of pharmaceuticals. Effective and eco-friendly strategies of biofabrication are also highlighted. Modern approaches to designing pharmaceutical nanoformulations (e.g., 3D printing, Phyto-Nanotechnology, Biomimetics/Bioinspiration, etc.) are outlined. This paper discusses the need to use natural resources for the "green" design of new nanoformulations with therapeutic efficiency. Nanopharmaceuticals research is still in its early stages, and the preparation of nanomaterials must be carefully considered. Therefore, safety and long-term effects of pharmaceutical nanoformulations must not be overlooked. The testing of nanopharmaceuticals represents an essential point in their further applications. Vegetal scaffolds obtained by decellularizing plant leaves represent a valuable, bioinspired model for nanopharmaceutical testing that avoids using animals. Nanoformulations are critical in various fields, especially in pharmacy, medicine, agriculture, and material science, due to their unique properties and advantages over conventional formulations that allows improved solubility, bioavailability, targeted drug delivery, controlled release, and reduced toxicity. Nanopharmaceuticals have transitioned from experimental stages to being a vital component of clinical practice, significantly improving outcomes in medical fields for cancer treatment, infectious diseases, neurological disorders, personalized medicine, and advanced diagnostics. Here are the key points highlighting their importance. The significant challenges, opportunities, and future directions are mentioned in the final section. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
37. Advances in the treatment of hyperuricemia with traditional Chinese medicine.
- Author
-
Gong Fang and Wenxi Li
- Subjects
CHINESE medicine ,HYPERURICEMIA ,NANOMEDICINE ,CHINESE literature ,DRUG target ,METABOLIC disorders - Abstract
Copyright of Journal of Chinese Pharmaceutical Sciences is the property of Journal of Chinese Pharmaceutical Sciences and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
38. Quantum Dot Research in Breast Cancer: Challenges and Prospects.
- Author
-
Omidian, Hossein, Wilson, Renae L., and Cubeddu, Luigi X.
- Subjects
BREAST cancer research ,QUANTUM dots ,TRIPLE-negative breast cancer ,DRUG delivery systems ,EARLY detection of cancer - Abstract
The multifaceted role of quantum dots (QDs) in breast cancer research highlights significant advancements in diagnostics, targeted therapy, and drug delivery systems. This comprehensive review addresses the development of precise imaging techniques for early cancer detection and the use of QDs in enhancing the specificity of therapeutic delivery, particularly in challenging cases like triple-negative breast cancer (TNBC). The paper also discusses the critical understanding of QDs' interactions with cancer cells, offering insights into their potential for inducing cytotoxic effects and facilitating gene therapy. Limitations such as biocompatibility, toxicity concerns, and the transition from laboratory to clinical practice are critically analyzed. Future directions emphasize safer, non-toxic QD development, improved targeting mechanisms, and the integration of QDs into personalized medicine, aiming to overcome the current challenges and enhance breast cancer management. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
39. Editorial: Augmented neuro-therapy with nanotechnology-based formulations: progress, opportunities and challenges.
- Author
-
Rajput, Mithun Singh, Patel, Viral, Nirmal, Nilesh Prakash, and Kumar, Dileep
- Subjects
NANOMEDICINE ,DRUG delivery systems ,HUNTINGTON disease ,HEDONIC damages ,THERAPEUTICS ,FERULIC acid ,NERVE growth factor - Abstract
This document is an editorial published in Frontiers in Pharmacology titled "Augmented neuro-therapy with nanotechnology-based formulations: progress, opportunities and challenges." The editorial discusses the use of nanotechnology-based formulations in neurotherapeutics as a novel strategy for neuroprotection. It highlights the potential benefits of using nanomedicine, such as increased bioavailability, reduced dosage and frequency, and elimination of associated toxicity. The editorial also presents four papers included in the Research Topic, which cover different aspects of neuroprotection using natural products combined with nanotechnology. These papers explore the neuroprotective effects of herbal extracts, such as Huperzia serrata and Centella asiatica, as well as the potential use of engeletin and cyclodextrin-based nanocomplexes in the treatment of neurological disorders. The editorial concludes by emphasizing the promising future of nanotechnology in central nervous system drug delivery and its potential to revolutionize neurotherapeutics. [Extracted from the article]
- Published
- 2024
- Full Text
- View/download PDF
40. Biomimetic Nanoparticles for Cancer Therapy: A Review of Recent Advances, Applications, and Bottlenecks
- Author
-
Issaka, Eliasu and Amu-Darko, Jesse Nii Okai
- Published
- 2024
- Full Text
- View/download PDF
41. Hot technology and technical evolution of polypeptide nanotechnology in medical application field based on patent data analysis
- Author
-
Zhao, Kai, Wu, Tong, Wei, Donglin, and Yuan, Hongmei
- Published
- 2024
- Full Text
- View/download PDF
42. Advances in the study of polydopamine nanotechnology in central nervous system disorders.
- Author
-
Sijing Ren, Xiangyu Xiao, Jiahua Lv, Shaomin Lv, Xingchen Wang, Ruihan Liu, and Qing-xia Kong
- Subjects
CENTRAL nervous system ,BLOOD-brain barrier ,PATHOLOGY ,REACTIVE oxygen species ,ALZHEIMER'S disease ,NANOTECHNOLOGY ,NANOMEDICINE - Abstract
Disorders of the central nervous system (CNS) constitute a significant global health concern at the moment. Most CNS disorders are characterized by severe neuronal damage with excessive production of reactive oxygen species, which induces high levels of oxidative stress and intense inflammatory responses in the affected tissues, thus aggravating disease pathology. Notably, the blood-brain barrier makes it difficult to deliver many drugs and biologics to the CNS, which creates great difficulties in the diagnosis and treatment of CNS disorders. Recent research on polydopamine nanotechnology has led to the discovery of many promising properties; it shows strong scavenging ability for reactive oxygen species, prevents activation of pro-inflammatory microglia, and its repair function can reduce brain damage and protect neurons. Moreover, polydopamine nanotechnology can improve the blood-brain barrier permeability of biologics and reduce their neurotoxicity. It is therefore a promising candidate in the treatment of CNS disorders associated with oxidative stress. In the present paper, we review the functionality of polydopamine nanotechnology as well as the potential and recent advances of polydopaminebased nanosystems in the diagnosis and treatment of various CNS disorders, including Alzheimer's disease, Parkinson's disease, stroke, spinal cord injury, and glioma. Finally, we predict how polydopamine nanoparticles may guide future therapeutic strategies to address CNS disorders such as epilepsy, which currently have no cure. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
43. 中药单体及复方在膝骨关节炎中的治疗进展.
- Author
-
莫 坚, 叶森涛, and 章晓云
- Subjects
VASCULAR endothelial growth factors ,KNEE osteoarthritis ,CHINESE medicine ,KNEE ,DEGENERATION (Pathology) ,INFLAMMATION ,ENDOCHONDRAL ossification ,NANOMEDICINE ,KNEE braces - Abstract
Copyright of Chinese Journal of Tissue Engineering Research / Zhongguo Zuzhi Gongcheng Yanjiu is the property of Chinese Journal of Tissue Engineering Research and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
- Published
- 2024
- Full Text
- View/download PDF
44. Piquing artificial intelligence towards drug discovery: Tools, techniques, and applications.
- Author
-
Agu, Peter Chinedu and Obulose, Chidiebere Nwiboko
- Subjects
- *
DRUG discovery , *ARTIFICIAL intelligence , *DRUG design , *DRUG development , *NANOMEDICINE , *DRUG toxicity - Abstract
The purpose of this study was to discuss how artificial intelligence (AI) methods have affected the field of drug development. It looks at how AI models and data resources are reshaping the drug development process by offering more affordable and expedient options to conventional approaches. The paper opens with an overview of well‐known information sources for drug development. The discussion then moves on to molecular representation techniques that make it possible to convert data into representations that computers can understand. The paper also gives a general overview of the algorithms used in the creation of drug discovery models based on AI. In particular, the paper looks at how AI algorithms might be used to forecast drug toxicity, drug bioactivity, and drug physicochemical properties. De novo drug design, binding affinity prediction, and other AI‐based models for drug–target interaction were covered in deeper detail. Modern applications of AI in nanomedicine design and pharmacological synergism/antagonism prediction were also covered. The potential advantages of AI in drug development are highlighted as the evaluation comes to a close. It underlines how AI may greatly speed up and improve the efficiency of drug discovery, resulting in the creation of new and better medicines. To fully realize the promise of AI in drug discovery, the review acknowledges the difficulties that come with its uses in this field and advocates for more study and development. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
45. Decoding the perception of prescribers towards generic medicine: A bibliometric study.
- Author
-
Prasad T, Aditya and Panesar, Ashwani
- Subjects
SUPPLY & demand ,MEDICAL care ,BIBLIOMETRICS ,BIBLIOTHERAPY ,CHAIN stores ,SUSTAINABLE development ,NANOMEDICINE - Abstract
2008 can be considered a watershed year for generic medicine in India, as it saw the launch of the Jan Aushadi scheme, to provide cost-effective quality medicines to its populace, through special stores called Jan Aushadi stores. With more than 8800 stores, the scheme is touted as one of the world's largest pharmaceutical retail chains. Since then, many generic medicine start-ups have also launched operations in the country- Zeno Health, One India Pharmacy, Generic Aadhaar and StayHappi Generics. These supply side developments will however have to be complemented with commensurate demand side responses for it make a sustainable impact towards the push for affordable and accessible healthcare for all (Sustainable Development Goal 3). Many studies have established that, on the demand side, owing to the lack of requisite medical knowledge on part of the patients, there exists a strong agency relationship, where patients rely heavily on their physicians (prescribers) to make decisions on choice of treatments. Though promotion of generic medicines requires a coordinated effort from many stakeholders, analysis reveals that the prescribers, and hence their perception of generics, plays a pivotal role in their adoption. This study undertakes a bibliometric analysis of the top 100 most-cited research papers published between 2012 and 2022 on the perception of prescribers towards generic medicine from SCOPUS database. Suitable keywords have been incorporated to reach the relevant publications and VOSviewer (version 1.6.10) has been used for analysis. The findings of the study recommend further research on interventions aimed at improving prescriber's perception towards generic medicines to enhance their adoption and promote cost effective healthcare delivery. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
46. A landscape of recent advances in lipid nanoparticles and their translational potential for the treatment of solid tumors.
- Author
-
Paun, Radu A., Jurchuk, Sarah, and Tabrizian, Maryam
- Subjects
TUMOR treatment ,NANOPARTICLES ,DRUG delivery systems ,CANCER prognosis ,SMALL molecules ,NANOMEDICINE ,POLYMERSOMES - Abstract
Lipid nanoparticles (LNPs) are biocompatible drug delivery systems that have found numerous applications in medicine. Their versatile nature enables the encapsulation and targeting of various types of medically relevant molecular cargo, including oligonucleotides, proteins, and small molecules for the treatment of diseases, such as cancer. Cancers that form solid tumors are particularly relevant for LNP-based therapeutics due to the enhanced permeation and retention effect that allows nanoparticles to accumulate within the tumor tissue. Additionally, LNPs can be formulated for both locoregional and systemic delivery depending on the tumor type and stage. To date, LNPs have been used extensively in the clinic to reduce systemic toxicity and improve outcomes in cancer patients by encapsulating chemotherapeutic drugs. Next-generation lipid nanoparticles are currently being developed to expand their use in gene therapy and immunotherapy, as well as to enable the co-encapsulation of multiple drugs in a single system. Other developments include the design of targeted LNPs to specific cells and tissues, and triggerable release systems to control cargo delivery at the tumor site. This review paper highlights recent developments in LNP drug delivery formulations and focuses on the treatment of solid tumors, while also discussing some of their current translational limitations and potential opportunities in the field. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
47. Effectiveness of Nanotechnology Treatments in Composite Aircraft Applications.
- Author
-
Cestino, Enrico, Catapano, Juri, Galvano, Francesco, Felis, Andrea, Zuccalà, Sabrina, Martilla, Valentina, Sapienza, Vito, and Chesta, Lorenzo
- Subjects
ALUMINUM alloys ,COMPOSITE materials ,AIRCRAFT noise ,FATIGUE life ,NANOMEDICINE - Abstract
This paper aims to verify the effectiveness of a process of superficial protection based on nanotechnologies produced by 4Ward360 and specifically developed for aeronautical applications on composite material aircraft. The Dardo aircraft, a composite VLA category manufactured by CFM Air, was taken as a reference case and two application/investigation areas were identified. The potential anticorrosive behavior of the nanotechnology treatment was investigated when applied to the metal joints of the aircraft, such as the wing–fuselage attachments usually made of Al-2024-T3 aluminum alloy. Furthermore, the potential increased effectiveness in cleaning was investigated as another possible application concerning the parts made of composite material both solid and in a sandwich configuration and the plexiglass parts of the canopy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
48. Research Advances in Superabsorbent Polymers.
- Author
-
Yang, Yaoyao, Liang, Zhiyuan, Zhang, Rui, Zhou, Shengwei, Yang, Haobo, Chen, Yanyu, Zhang, Jiahui, Yin, Hongyi, and Yu, Dengguang
- Subjects
SUPERABSORBENT polymers ,BIOPOLYMERS ,GRAFT copolymers ,POLYVINYL alcohol ,POLYACRYLIC acid ,POLYACRYLAMIDE - Abstract
Superabsorbent polymers are new functional polymeric materials that can absorb and retain liquids thousands of times their masses. This paper reviews the synthesis and modification methods of different superabsorbent polymers, summarizes the processing methods for different forms of superabsorbent polymers, and organizes the applications and research progress of superabsorbent polymers in industrial, agricultural, and biomedical industries. Synthetic polymers like polyacrylic acid, polyacrylamide, polyacrylonitrile, and polyvinyl alcohol exhibit superior water absorption properties compared to natural polymers such as cellulose, chitosan, and starch, but they also do not degrade easily. Consequently, it is often necessary to modify synthetic polymers or graft superabsorbent functional groups onto natural polymers, and then crosslink them to balance the properties of material. Compared to the widely used superabsorbent nanoparticles, research on superabsorbent fibers and gels is on the rise, and they are particularly notable in biomedical fields like drug delivery, wound dressing, and tissue engineering. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
49. Managing Colorectal Cancer from Ethology to Interdisciplinary Treatment: The Gains and Challenges of Modern Medicine.
- Author
-
Berbecka, Monika, Berbecki, Maciej, Gliwa, Anna Maria, Szewc, Monika, and Sitarz, Robert
- Subjects
COLORECTAL cancer ,ANIMAL behavior ,GENERAL practitioners ,GASTROINTESTINAL tumors ,MEDICAL screening ,NANOMEDICINE ,CETUXIMAB - Abstract
Colorectal cancer (CRC) is a common malignant tumor of the gastrointestinal tract, which has become a serious threat to human health worldwide. This article exhaustively reviews colorectal cancer's incidence and relevance, carcinogenesis molecular pathways, up-to-date treatment opportunities, prophylaxis, and screening program achievements, with attention paid to its regional variations and changes over time. This paper provides a concise overview of known CRC risk factors, including familial, hereditary, and environmental lifestyle-related risk factors. The authors take a closer look into CRC's molecular genetic pathways and the role of specific enzymes involved in carcinogenesis. Moreover, the role of the general practitioner and multidisciplinary approach in CRC treatment is summarized and highlighted based on recent recommendations and experience. This article gives a clear understanding and review of the gains and challenges of modern medicine towards CRC. The authors believe that understanding the current patterns of CRC and its revolution is imperative to the prospects of reducing its burden through cancer prevention and cancer-adjusted treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
50. Research progress on graphene oxide nanoparticle-based diagnosis and treatment platform in tumor therapy.
- Author
-
Jiang, Jiacheng, Qiu, Xiaonan, Zhu, Wenrong, and Deng, Chunmin
- Subjects
GRAPHENE oxide ,TUMOR treatment ,NANOMEDICINE ,CONTROLLED release drugs ,TUMOR diagnosis ,NANOPARTICLES - Abstract
Tumors are significant diseases that pose a substantial threat to human health. Presently, there are diverse methods for diagnosing and treating tumors in clinical. However, real-time monitoring of the distribution of tumor cells within the body and precise tumor eradication remains a challenge. Recently, with the advancement of nanotechnology, the utilization of nanoparticle has enabled real-time monitoring of tumor cells migration and distribution within the body, as well as controlled and sustained drug release tailored to the specific tumor microenvironment (TME). This achievement has facilitated precise tumor eradication. Among various nanoparticle, graphene oxide (GO) boasts a substantial-specific surface area, which not only allows efficient drug loading but also effectively quenches the fluorescence signal of diagnostic molecules. When GO reaches the tumor tissue, the high concentration of glutathione (GSH) in the tumor environment reduces GO into reduced graphene oxide (rGO). This reduction triggers the release of fluorescent diagnostic molecules from its surface, leading to the restoration of their fluorescence signal and enabling timely tumor diagnosis. Furthermore, GO possesses strong near-infrared absorption and thermal conductivity properties. Hence, utilizing GO-based photothermal therapy, in addition to leverage its excellent photothermal conversion efficiency for direct tumor cells ablation, it achieves precise and sustained drug release based on the specific TME. Exploiting the distinctive biological properties of GO, this paper aims to provide a comprehensive overview of the latest research and related progress in the utilization of GO as a carrier for drugs and diagnostic agents in the realms of tumor diagnosis and precision treatment. First, we describe the biochemistry of GO and its application as a fluorescence quencher in tumor diagnosis. Second, capitalizing on GO's substantial surface area and environment-responsive attributes, we delve into the research progress of GO in tumor treatment. Finally, we summarize GO's biocompatibility as a drug carrier for tumor diagnosis and treatment while also discussing its future prospects. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.